Finny logo
Finny logo
Dibs:
Dibs:
0

Dova Pharmaceuticals (DOVA) is down today: does this make sense?

1:03 pm ET, 21 May 2018

Dova Pharmaceuticals (NASDAQ: DOVA) today announced the FDA has completed their Priority Review and approved DOPTELET for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD), but the stock is down 11% in mid-day trading today.  

What's driving this?  Are the 'big guys' liquidating their investments?  Are retail investors 'panic-selling' their shares?

The technical analysis shows weak mid-term prospects, although the short- and the long-term outlook appear pretty strong.  

S&P Capital IQ analysis shows relatively poor financial health and growth stability of the DOVA stock.  Growth Stability is an assessment of how stable the growth of earnings and cash flow has been over time.  Financial Health uses fundamental data to view the company’s debt and interest obligations (among other factors) to its financial health in comparison to its peers. 

Per Finstead research, the analyst consensus price target is $38.  With the recent price drop, there could be even a larger upside.  Currently, three analysts are covering the stock.     

DOVA is a small-cap stock, so it's more volatile than S&P 500 company shares.  There is nothing in our analysis that shows an immediate sign of worry for investors to sell their stock.  

It's likely that DOVA will bounce back in the near future. 

The DOPTELET medication is really a breakthrough.  It is the first orally administered treatment option for patients with chronic liver disease, allowing the majority of patients to avoid a platelet transfusion prior to a procedure by increasing platelet counts to the target level of greater or equal to 50,000 per microliter. The company plans to launch DOPTELET in June with our full complement of sales, marketing, and support resources.

Dova Pharmaceuticals, Inc. (DOVA) Stock Guide

Updated at: 7:06 am ET, 14 Nov 2020

Before we start: if you're looking for DOVA stock price, you can quickly find it out by visiting Finny and typing "DOVA quote". If you're looking for a quick scoop on DOVA stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "DOVA". You'll get all this info in one place. Or you can just type "DOVA news" to get the latest stock news.

Looking to buy or sell Dova Pharmaceuticals, Inc. (DOVA)? Interested in getting the full scoop on DOVA, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this DOVA stock guide, we'll address key questions about DOVA, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. DOVA buy or sell? What is DOVA Finny Score?
2. What are the reasons to buy DOVA? Why should I buy DOVA stock?
3. What are the reasons to sell DOVA? Why should I sell DOVA stock?
4. What are DOVA key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Analysis

1. DOVA buy or sell? What is DOVA Finny Score?

#{finnyScore:null}Our quantitative analysis shows 0 reasons to buy and 1 reason to sell DOVA. DOVA doesn’t have an assigned Finny Score, because we don’t have sufficient data points to score the stock.

2. What are the reasons to buy DOVA? Why should I buy DOVA stock?

We can’t think of any good reason to buy this stock, which doesn’t mean they don’t exist.

3. What are the reasons to sell DOVA? Why should I sell DOVA stock?

Let's look at the reasons to sell DOVA stock (i.e., the bear case):

  • DOVA stock price ($28.04) is close to the 52-week high ($28.51). Perhaps now is a good time to sell? See DOVA price chart.

Key Stats

4. What are DOVA key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for DOVA:

Metrics DOVA
Price $28.06
Average Price Target / Upside N/A
Average Analyst Rating N/A
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 115
Market Cap $00
Forward P/E Ratio N/A
Price/Book Ratio N/A
Revenue (TTM) N/A
YoY Quarterly Revenue Growth N/A
Profit Margin N/A

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us